All In Biotech

Drug Trial Radar · NCT06188559

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2) Antibody-drug Conjugate (ADC), in Previously Treated Subjects With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Apr 10, 2024

Primary completion

Mar 18, 2026

Study completion Mar 18, 2026

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).

Conditions

  • Breast Cancer

Interventions

  • BB-1701Drug

    BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, Dose Optimization: Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 35 months
  2. Part 1, Dose Optimization: Number of Participants With Clinically Significant Laboratory ValuesTime frame: Baseline up to 35 months
  3. Part 1, Dose Optimization: Number of Participants With Clinically Significant Vital Sign ValuesTime frame: Baseline up to 35 months
  4. Part 1, Dose Optimization: Number of Participants With Clinically Significant 12-lead ECGs ValuesTime frame: Baseline up to 35 months
  5. Part 1, Dose Optimization: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)Time frame: Baseline up to 35 months
  6. Part 1, Dose Optimization: Objective Response Rate (ORR)Time frame: From date of first dose of study drug until first documentation of CR or PR (up to 35 months)
  7. Part 2, Dose Expansion: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment per RECIST v1.1Time frame: From date of first dose of study drug until first documentation of CR or PR (up to 35 months)

Locations

49 sites in 4 countries. Site status is shown where the registry gives one.

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • UCLA Center for East-West Medicine

    Los Angeles, California

  • UCSF

    San Francisco, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • AdventHealth Cancer Institute - Orlando

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Fort Wayne Medical Oncology & Hematology

    Fort Wayne, Indiana

  • Community Cancer Center South

    Indianapolis, Indiana

  • Mission Blood and Cancer

    Des Moines, Iowa

  • University of Michigan Hospital

    Ann Arbor, Michigan

  • Washington University in St. Louis School of Medicine

    St Louis, Missouri

  • NHO Revive Research Institute LLC

    Lincoln, Nebraska

  • Nebraska Cancer Specialist

    Omaha, Nebraska

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Summit Medical Group

    Florham Park, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • New Mexico Oncology Hematology Consultants

    Albuquerque, New Mexico

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center)

    Cleveland, Ohio

  • Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Oncology Specialists

    Salem, Oregon

  • UPMC CancerCenter at Magee - Womens Hospital

    Pittsburgh, Pennsylvania

  • St. Francis Cancer Center

    Greenville, South Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • The West Clinic, PLLC dba West Cancer Cente

    Germantown, Tennessee

  • Northwest Medical Specialties

    Puyallup, Washington

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France

  • Institut Régional du Cancer de Montpellier

    Montpellier, France

  • Centre Armoricain de Radiotherapie Imagerie & Oncologie (CARIO)

    Plérin, France

  • Institut de Cancerologie de Ouest (ICO) - Saint-Herblain

    Saint-Herblain, France

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Hiroshima, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Hyogo Medical University Hospital

    Nishinomiya-shi, Hyōgo, Japan

  • Sagara Hospital, Social Medical Corporation Hakuaikai

    Kagoshima, Kagoshima-ken, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Kyoto University Hospital

    Sakyo-ku, Kyoto, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.